Trial Profile
A single-center retrospective study of anlotinib in metastatic renal cell carcinoma
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 15 Oct 2021
Price :
$35
*
At a glance
- Drugs Catequentinib (Primary)
- Indications Renal cell carcinoma
- Focus Adverse reactions; Therapeutic Use
- 15 Oct 2021 New trial record